Compare AbCellera Biologics Inc (ABCL) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs TotalEnergies SE — how do they compare? AbCellera Biologics Inc trades at $10.33 (market cap $2.99B), while TotalEnergies SE trades at $86.9 (market cap $196.06B). The key difference: TotalEnergies SE is far larger — about 65.6× AbCellera Biologics Inc's market cap, and TotalEnergies SE pays a 4.82% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | TTE | |
|---|---|---|
Market Cap | $2.99B | $196.06B |
Sector | Health | Energy |
52-Week High | $9.76 | $93.60 |
52-Week Low | $2.78 | $57.39 |
Enterprise Value | $2.58B | $227.06B |
Dividend Yield | — | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $10.34, up 10.71% on positive Phase 2 trial results for its menopause drug ABCL635, which showed 83% reduction in hot flashes. Despite negative profitability metrics, the stock maintains strong analyst support with 91.7% buy ratings and a $15.50 consensus target. Technical indicators show bullish momentum with the price near resistance at $11, though RSI levels suggest overbought conditions.
The outlook remains speculative given ongoing losses but is supported by promising clinical data and strategic partnerships. Key risks include drug development timelines, cash burn, and reliance on successful commercialization. Upside potential exists if ABCL635 advances successfully through regulatory phases.
TotalEnergies (TTE) trades at $87.46, down 0.57% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed quarterly beats, while revenue declined to $182.34B in 2025. The company is expanding in renewables, acquiring Shell's European onshore renewables business and partnering on a Cyprus gas field development.
TTE offers value with a P/E of 11.01 and a 57.58% buy rating from analysts, targeting $94.00. Risks include declining revenue trends, legal challenges from climate litigation, and oil price volatility. The stock presents a balanced opportunity with income from dividends but faces execution risks in energy transition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
